Login / Signup

Comparative Effectiveness of Switching to Bictegravir From Dolutegravir-, Efavirenz-, or Raltegravir-Based Antiretroviral Therapy Among Individuals With HIV Who are Virologically Suppressed.

Isaac NúñezYanink Caro-VegaConor James MacDonaldJuan Luis Mosqueda-GómezAlicia Piñeirúa-MenéndezAnthony A Matthews
Published in: Open forum infectious diseases (2024)
Our findings suggest that switching to bictegravir could be more effective in maintaining viral suppression than continuing with dolutegravir, efavirenz, or raltegravir.
Keyphrases
  • antiretroviral therapy
  • hiv infected patients
  • hiv infected
  • hiv positive
  • human immunodeficiency virus
  • hiv aids
  • sars cov
  • medical education
  • hepatitis c virus